Tengonermin

N/A

Report date: 2024/11/19 13:08:59

Base Information

Drug NameTengonermin
Drug Alias NameARENEGYRCNGRC peptide-TNF alpha conjugateNGR-TNFαNGR-hTNFNGR-TNF +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionTumor necrosis factor receptor modulatorsAngiogenesis inhibitorsAminopeptidase N modulators
TargetsAminopeptidase NTumor necrosis factor receptor
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMolmed Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAgc Biologics
Active IndicationsN/A
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[10] 

Other Information

ATC CodeN/A
Related LinksWikipedia